Free Trial
NASDAQ:MREO

Mereo BioPharma Group Q4 2024 Earnings Report

Mereo BioPharma Group logo
$2.06 +0.10 (+5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.00 (+0.24%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mereo BioPharma Group EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.02
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Mereo BioPharma Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$72.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mereo BioPharma Group Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Mereo BioPharma Group's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Mereo BioPharma Group Earnings Headlines

Is Nvidia about to Trigger Another 150X Opportunity?
Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics processing units. Legendary investor Louis Navellier believes this new invention could be even more revolutionary and mint a new wave of millionaires.tc pixel
See More Mereo BioPharma Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mereo BioPharma Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mereo BioPharma Group and other key companies, straight to your email.

About Mereo BioPharma Group

Mereo BioPharma Group (NASDAQ:MREO) plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases. Additional clinical programs target oncology and immunology indications, leveraging both internally developed molecules and partnerships with third-party biotech and pharmaceutical companies. The company conducts multi‐center trials in Europe and North America, collaborating with academic institutions and contract research organizations to advance its clinical objectives.

Established in 2013 and headquartered in London, Mereo BioPharma has built a team with expertise in clinical development, regulatory affairs and corporate strategy to support its focused portfolio. The company’s business strategy emphasizes strategic alliances, out-licensing opportunities and selective acquisitions to enhance shareholder value and ensure sustained progress across its pipeline. Mereo is listed on the NASDAQ under the ticker symbol MREO and maintains operations in the United Kingdom, United States and Europe.

View Mereo BioPharma Group Profile

More Earnings Resources from MarketBeat